TCGA-55-6642-01A-11R-1858-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- ANGIOGENESIS+0.460
- TGF_BETA_SIGNALING+0.410
- UV_RESPONSE_DN+0.390
- PROTEIN_SECRETION+0.380
- ANDROGEN_RESPONSE+0.300
- MITOTIC_SPINDLE+0.280
- NOTCH_SIGNALING+0.270
- UNFOLDED_PROTEIN_RESPONSE+0.270
- HEDGEHOG_SIGNALING+0.260
Top 10 suppressed
- MYC_TARGETS_V2-0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- E2F_TARGETS-0.380
- DNA_REPAIR-0.360
- OXIDATIVE_PHOSPHORYLATION-0.330
- P53_PATHWAY-0.290
- MYC_TARGETS_V1-0.250
- PANCREAS_BETA_CELLS-0.240
- KRAS_SIGNALING_DN-0.220
- XENOBIOTIC_METABOLISM-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-86-8055-01A-11R-2241-07 | — | cohortA1 | 0.851 |
| 2 | TCGA-44-6774-01A-21R-1858-07 | — | cohortA1 | 0.848 |
| 3 | SRR6013569 | — | cohortMD2 | 0.839 |
| 4 | TCGA-64-1679-01A-21R-2066-07 | — | cohortA1 | 0.837 |
| 5 | TCGA-BH-A1EO-01A-11R-A137-07 | — | A | 0.825 |
| 6 | TCGA-97-7554-01A-11R-2039-07 | — | cohortA1 | 0.811 |
| 7 | TCGA-AR-A24T-01A-11R-A169-07 | — | A | 0.809 |
| 8 | SRR5088836 | — | — | 0.806 |
| 9 | a6105a18-de2b-470c-bbb1-8c1188c57e22 | — | — | 0.800 |
| 10 | TCGA-BH-A0H3-01A-11R-A12P-07 | — | A | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |